Aflibercept for Diabetic Macular Edema In Real-life Practice in GREece (ADMIRE)

National and Kapodistrian University of Athens

Status: Completed

Conditions: Diabetic Macular Edema

Treatments: Drug: Aflibercept

Study type: Observational

Funder types: Other

Identifiers

NCT05683912

698/2019

Details and patient eligibility

About

ADMIRE was a prospective, observational cohort study of patients with diabetic macular edema (DME). Efficacy was assessed by change in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) from baseline to months 12, 24 and 36 after treatment with intravitreal aflibercept in treatment-naïve patients and previously treated patients. Safety was evaluated by recording any patients-reported events.

Enrollment: 100 patients

Sex: All

Ages: 45+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients with DM, able to give written informed consent Patients with DME>320 μm, who need treatment

Exclusion criteria

Patients with other retinal diseases than DME Intraocular surgery within the last 6 months